Sophie Béliard

Dr. Sophie Béliard

APHM, Metabolic Diseases, Endocrinology, Department of Nutrition, 13385 Marseille, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2015 in Diabetes Care
Verified
Journal Article
Open access
PDF file
CGCaroline Gaudy
Caroline Gaudy
CCCéline Clévy
Céline Clévy
SMSandrine Monestier
Sandrine Monestier
NDNoémie Dubois
Noémie Dubois
YPYanis Préau
Yanis Préau
SBSophie Béliard
Sophie Béliard

1 August 2020 in Atherosclerosis
Verified
Journal Article
Closed access
AGAntonio Gallo
Antonio Gallo
SCSybil Charriere
Sybil Charriere
AVAlexandre Vimont
Alexandre Vimont
MCM. John Chapman
M. John Chapman
DADenis Angoulvant
Denis Angoulvant
OZOlivier Ziegler
Olivier Ziegler

1 October 2018 in Atherosclerosis
Verified
Journal Article
Open access
SBSophie Béliard
Sophie Béliard
FBFranck Boccara
Franck Boccara
BCBertrand Cariou
Bertrand Cariou
ACAlain Carrié
Alain Carrié
XCXavier Collet
Xavier Collet
OZO. Ziegler
O. Ziegler
Cardiovascular risk is high in heterozygous familial hypercholesterolemia (HeFH). The objective of this study was to describe recurrent cardiovascular events in selected patients with HeFH attending lipid clinics in France. We included 781 patients with a clinical (Dutch Lipid Clinic Network score ≥ 6) or genetic diagnosis of HeFH who had experienced a first cardiovascular event (myocardial infarction, percutaneous coronary intervention or coronary bypass, unstable angina, stroke, peripheral arterial revascularization or cardiovascular death) and were enrolled in the French Familial Hypercholesterolemia Registry (November 2015 to March 2018). The first cardiovascular event occurred at the mean age of 47 years (interquartile range 39-55) in a predominantly male population (72%); 48% of patients were on statin therapy. Overall, 37% of patients had at least one recurrent cardiovascular event (mean of 1.8 events per patient), of which 32% occurred in the 12 months after the index event; 55% of events occurred >3 years after the first event. Mean LDL-C at the last clinic visit was 144 ± 75 mg/dL (132 ± 69 mg/dL for patients on high-potency statin therapy and 223 ± 85 mg/dL for untreated patients). The rate of recurrent cardiovascular events was high in French patients with HeFH in secondary prevention. The detection of FH during childhood is crucial to prevent CV events at a young age by early initiating statin therapy. There is a clear urgent need to expand the actual very small target population which can be treated with the PCSK9 inhibitor in France.

1 June 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
SBSophie Béliard
Sophie Béliard
SSSamir Saheb
Samir Saheb
SLStéphanie Litzler-Renault
Stéphanie Litzler-Renault
AVAlexandre Vimont
Alexandre Vimont
RVRENE VALERO
RENE VALERO
AGAntonio Gallo
Antonio Gallo
BACKGROUND: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal antibody, more than halves low-density lipoprotein cholesterol in short-term studies. This study evaluated whether the evinacumab response was durable in the long term and improved cardiovascular outcome. METHODS: The OLE ELIPSE HoFH (Open-Label Extension to Evinacumab Lipid Studies in Patients With HoFH) study included newly diagnosed patients and those completing the ELIPSE HoFH trial, on stable lipid-lowering therapy including lipoprotein apheresis but not lomitapide. All patients received evinacumab (15 mg/kg intravenously) every 4 weeks, with no change in concomitant lipid-lowering treatment during the first 6 months. The primary efficacy end points were the mean absolute and percentage changes in low-density lipoprotein cholesterol from baseline to 6 months. A key secondary end point was cardiovascular event–free survival, which was compared with a control HoFH cohort not treated with evinacumab or lomitapide and matched for age, sex, and lipoprotein apheresis, derived from French Registry of Familial hypercholesterolemia. RESULTS: Twelve patients, 5 women and 7 men (12–57 years), were enrolled in 3 centers in France. At 6 months, the mean low-density lipoprotein cholesterol reduction with evinacumab was 3.7 mmol/L or 56% (from 6.5 mmol/L at baseline to 2.8 mmol/L; P <0.0001) and was sustained over the median 3.5-year follow-up. No patients on evinacumab experienced cardiovascular events versus 13 events for 5/21 (24%) over 4 years in the control cohort (likelihood P =0.0267). CONCLUSIONS: Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event–free survival of patients with HoFH.

1 April 2021 in Metabolism
Verified
Journal Article
Closed access
LPLéa Pietri
Léa Pietri
RGRoch Giorgi
Roch Giorgi
ABAudrey Bégu
Audrey Bégu
MLManon Lojou
Manon Lojou
MKMarie Koubi
Marie Koubi
SBSophie Béliard
Sophie Béliard

8 September 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LDLaura D'Erasmo
Laura D'Erasmo
AGAntonio Gallo
Antonio Gallo
Angelo Baldassare CefaluAngelo Baldassare Cefalu
Angelo Baldassare Cefalu
DADi Costanzo Alessia
Di Costanzo Alessia
SSSamir Saheb
Samir Saheb
EBEric Bruckert
Eric Bruckert
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Italy (n = 30) and the other with LA in France (n = 29). Results: The two cohorts differed significantly for genotype (p = 0.004), baseline lipid profile (p < 0.001), age of treatment initiation (p < 0.001), occurrence of cardiovascular disease (p = 0.003) as well as follow-up duration (p < 0.001). The adjunct of lomitapide to conventional lipid-lowering therapies determined an additional 58.0% reduction of last visit LDL-C levels, compared to 37.1% when LA was added (padj = 0.004). Yearly on-treatment LDL-C < 70 mg/dl and < 55 mg/dl goals were only achieved in 45.5% and 13.5% of HoFH patients treated with lomitapide. The long-term exposure to LDL-C burden was found to be higher in LA than in Lomitapide cohort (13,236.1 ± 5492.1 vs. 11,656.6 ± 4730.9 mg/dL-year respectively, padj = 0.002). A trend towards fewer total cardiovascular events was observed in the Lomitapide than in the LA cohort. Conclusions: In comparison with LA, lomitapide appears to provide a better control of LDL-C in HoFH. Further studies are needed to confirm this data and establish whether this translates into a reduction of cardiovascular risk.